SMAD4 and colorectal carcinoma: Recent studies have shown that the TGFBR2 genotype is the major factor determining a lack of EMT-like responses to TGFβ1 in MSI-positive tumors, whereas CRC cells with SMAD4 mutations retain the ability to undergo EMT upon TGFβ1 treatment through coupling with the ERK pathway [22].